Abstract
It is well known that patients with cancer may subsequently develop secondary/therapy-related neoplasms, generally exhibiting poorer prognosis than their de novo counterparts.1 Among patients with myeloproliferative neoplasms (MPN), there may be a higher rate of second malignancies before, concomitant with, or after their MPN diagnosis as compared with the general population2-9 (Table 1). We recently reported (and others confirmed) the association of lymphoid malignancies coexistent with an MPN diagnosis and found this to be an overall rare phenomenon that did not predict for worse clinical outcomes among MPN patients.10 The incidence and relative risk of post-MPN lymphoid neoplasms has been evaluated, and a 1.4- to 5-fold higher risk in this population has been identified, regardless of therapy received (Table 1). A recent important report in this area raises the possibility that those patients with MPN treated with a Janus kinase (JAK) inhibitor class of therapies may have a markedly higher rate of development of a subsequent lymphoma than patients who did not receive these therapies.11 Given the paucity of data sets that specifically focus on those patients with MPN treated with a JAK inhibitor subsequently diagnosed with a lymphoma, we sought to determine the characteristics and outcomes of this particular subset of patients in our large patient database.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2348-2351 |
| Number of pages | 4 |
| Journal | Blood |
| Volume | 133 |
| Issue number | 21 |
| DOIs | |
| State | Published - May 23 2019 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. / Pemmaraju, Naveen; Kantarjian, Hagop; Nastoupil, Loretta; Dupuis, Megan; Zhou, Lisa; Pierce, Sherry; Patel, Keyur P.; Masarova, Lucia; Cortes, Jorge; Verstovsek, Srdan.
In: Blood, Vol. 133, No. 21, 23.05.2019, p. 2348-2351.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy
AU - Pemmaraju, Naveen
AU - Kantarjian, Hagop
AU - Nastoupil, Loretta
AU - Dupuis, Megan
AU - Zhou, Lisa
AU - Pierce, Sherry
AU - Patel, Keyur P.
AU - Masarova, Lucia
AU - Cortes, Jorge
AU - Verstovsek, Srdan
PY - 2019/5/23
Y1 - 2019/5/23
N2 - It is well known that patients with cancer may subsequently develop secondary/therapy-related neoplasms, generally exhibiting poorer prognosis than their de novo counterparts.1 Among patients with myeloproliferative neoplasms (MPN), there may be a higher rate of second malignancies before, concomitant with, or after their MPN diagnosis as compared with the general population2-9 (Table 1). We recently reported (and others confirmed) the association of lymphoid malignancies coexistent with an MPN diagnosis and found this to be an overall rare phenomenon that did not predict for worse clinical outcomes among MPN patients.10 The incidence and relative risk of post-MPN lymphoid neoplasms has been evaluated, and a 1.4- to 5-fold higher risk in this population has been identified, regardless of therapy received (Table 1). A recent important report in this area raises the possibility that those patients with MPN treated with a Janus kinase (JAK) inhibitor class of therapies may have a markedly higher rate of development of a subsequent lymphoma than patients who did not receive these therapies.11 Given the paucity of data sets that specifically focus on those patients with MPN treated with a JAK inhibitor subsequently diagnosed with a lymphoma, we sought to determine the characteristics and outcomes of this particular subset of patients in our large patient database.
AB - It is well known that patients with cancer may subsequently develop secondary/therapy-related neoplasms, generally exhibiting poorer prognosis than their de novo counterparts.1 Among patients with myeloproliferative neoplasms (MPN), there may be a higher rate of second malignancies before, concomitant with, or after their MPN diagnosis as compared with the general population2-9 (Table 1). We recently reported (and others confirmed) the association of lymphoid malignancies coexistent with an MPN diagnosis and found this to be an overall rare phenomenon that did not predict for worse clinical outcomes among MPN patients.10 The incidence and relative risk of post-MPN lymphoid neoplasms has been evaluated, and a 1.4- to 5-fold higher risk in this population has been identified, regardless of therapy received (Table 1). A recent important report in this area raises the possibility that those patients with MPN treated with a Janus kinase (JAK) inhibitor class of therapies may have a markedly higher rate of development of a subsequent lymphoma than patients who did not receive these therapies.11 Given the paucity of data sets that specifically focus on those patients with MPN treated with a JAK inhibitor subsequently diagnosed with a lymphoma, we sought to determine the characteristics and outcomes of this particular subset of patients in our large patient database.
UR - http://www.scopus.com/inward/record.url?scp=85065254485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065254485&partnerID=8YFLogxK
U2 - 10.1182/blood-2019-01-897637
DO - 10.1182/blood-2019-01-897637
M3 - Article
C2 - 30796023
AN - SCOPUS:85065254485
VL - 133
SP - 2348
EP - 2351
JO - Blood
JF - Blood
SN - 0006-4971
IS - 21
ER -